February 15, 2024 12:40 PM EST
Manufacturing

Charles Riv­er’s CD­MO rev­enue rise; Catal­ent lays off 300 staffers; Bio­gen’s idle ca­pac­i­ty

Anna Brown

News Reporter

Charles Riv­er’s over­all man­u­fac­tur­ing busi­ness saw a 9.5% de­crease in rev­enue in the last quar­ter of 2023 with $191.9 mil­lion, ver­sus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times